Not every company in biotech land is loved by investors. In fact, many biotechs top the list of companies with high short interest as a percentage of float.

As of the end of February, Myriad Genetics (NASDAQ:MYGN) was the second-most shorted company as a percentage of float. Sarepta Therapeutics (NASDAQ:SRPT) came in at No. 9. OncoMed Pharmaceuticals (NASDAQ:OMED)VIVUS (NASDAQ:VVUS), and MannKind (NASDAQ:MNKD) rounded out the top five most-shorted biotechs. 

In the slideshow below, you can see their metrics and reasons why some investors don't like them.

Fear not if your favorite biotech makes the list; Questcor Pharmaceuticals and Ziopharm Oncology, which were in last month's list, fell back in favor -- at least somewhat -- dropping off the top-five list.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.